Stately Bio's $12 Million Seed Backs a Label-Free Window Into Living Cells

The Palo Alto startup, founded by a former Calico machine learning lead, uses computer vision to track cell identity and quality in real time, aiming to improve regenerative medicine development.

About Stately Bio

Published

In the precise world of cell therapy, the most critical question is often the hardest to answer: what is happening inside the living cell, right now, without killing it to find out. Stately Bio, a Palo Alto startup that emerged from stealth in May 2025, is betting its machine learning platform can provide that continuous, non-destructive readout, offering a new temporal dimension to a field historically reliant on static, endpoint assays [Longevity.Technology, May 2025].

Founded in 2022 by former Calico Life Sciences machine learning lead Frank Li, the company announced a $12 million seed round led by AIX Ventures to scale its technology and advance an internal therapeutic program [PERPLEXITY SONAR PRO BRIEF, May 2025]. The round attracted a notable list of co-investors, including Dimension Capital, Foothill Ventures, and individual checks from Google DeepMind chief scientist Jeff Dean and ITA Software co-founder Jeremy Wertheimer [PERPLEXITY SONAR PRO BRIEF, May 2025].

The Label-Free Imaging Wedge

The company's core proposition is a platform that combines computer vision, machine learning, and live-cell imaging to identify and monitor cells using ordinary brightfield microscope images. The key differentiator is its label-free approach, meaning it does not require fluorescent tags, stains, or genetic modifications that can alter cell behavior or render them unusable for therapy [PERPLEXITY SONAR PRO BRIEF, May 2025]. By analyzing subtle morphological features in these images over time, the system aims to provide real-time information on cell identity, quality, and maturation state while preserving the cells for continued observation or therapeutic use [PERPLEXITY SONAR PRO BRIEF, May 2025].

This addresses a persistent bottleneck. Conventional methods for assessing cell quality often involve destructive sampling or intrusive labels, making it difficult to track the same population of cells as they differentiate and mature. For developers of stem-cell-derived therapies, this lack of a continuous feedback loop can slow optimization and increase the risk of batch failures. Stately's platform is designed to sit inside the development and manufacturing workflow, giving scientists a dynamic dashboard of cell health.

From Platform to Pipeline

Stately Bio is pursuing a dual-path strategy. Its primary commercial focus is partnering with cell-therapy developers, regenerative medicine companies, and pharmaceutical firms to integrate its analytical platform [PERPLEXITY SONAR PRO BRIEF, May 2025]. The company has cited a partnership with the New York Blood Center to more quickly identify specific subpopulations of stem-cell-derived immune cells [PERPLEXITY SONAR PRO BRIEF, May 2025].

Concurrently, it is developing its own internal therapeutic pipeline, starting with a liver program based on stem-cell differentiation. The company claims its internally developed protocols, guided by its imaging platform, have outperformed previous differentiation methods by 3 to 10 times on key, clinically relevant function assays [PERPLEXITY SONAR PRO BRIEF, May 2025]. This in-house program serves as both a proof-of-concept for the platform's utility and a potential future revenue stream.

The Founder's Pivot From Tech to Bio

The venture is a deliberate pivot for founder and CEO Frank Li. His background includes a stint as a machine learning lead at Calico, Alphabet's longevity-focused biotech subsidiary, which provided a front-row seat to the challenges of biological data analysis [PERPLEXITY SONAR PRO BRIEF, May 2025]. Prior to Calico, Li's career spanned investment roles at firms like Silver Lake and SoftBank Ventures Asia, and an earlier chapter as a co-founder of the mobile payments startup Clinkle [Bloomberg Markets, retrieved 2026] [TechCrunch, May 2015].

His trajectory from fintech and investing into hard biotech reflects a broader trend of computational talent migrating toward biology's unsolved problems. The seed round's investor composition underscores this, blending traditional venture capital with strategic corporate investment from Mitsui & Co. and validation from deep-tech angels like Jeff Dean.

Investor Type Notable Detail
AIX Ventures Lead Investor Led the $12M seed round [PERPLEXITY SONAR PRO BRIEF, May 2025]
Dimension Capital, Foothill Ventures, Village Global Venture Capital Participating investors [PERPLEXITY SONAR PRO BRIEF, May 2025]
Mitsui & Co. Global Investment Corporate Venture Strategic corporate participant [PERPLEXITY SONAR PRO BRIEF, May 2025]
Jeff Dean, Jeremy Wertheimer Angel Investors Google DeepMind chief scientist and ITA Software co-founder [PERPLEXITY SONAR PRO BRIEF, May 2025]

Navigating a High-Stakes Field

The ambition is significant, and so are the hurdles. Stately Bio is entering a field where regulatory pathways for novel process analytics are still evolving. Convincing drug developers to integrate a new, data-rich platform into their tightly controlled Good Manufacturing Practice (GMP) environments requires demonstrating not just technical superiority, but also robust validation and a clear impact on the bottom line,either by speeding development timelines or improving product consistency.

Furthermore, while the initial liver cell data is promising, it remains an internal benchmark. Independent peer-reviewed validation of the platform's predictive power across different cell types will be a crucial milestone for broader scientific and industry adoption. The company's success will hinge on translating its proprietary imaging signatures into universally accepted biomarkers of cell potency and safety.

  • Regulatory adoption. The platform must prove its fit within existing FDA and EMA frameworks for cell therapy manufacturing, where any new analytical method faces scrutiny.
  • Commercial scaling. Moving from research partnerships to embedded, revenue-generating deployments with large pharma represents a classic biotech software challenge.
  • Therapeutic risk. The resources devoted to the in-house liver program could divert focus from the platform business, though it also serves as a powerful demonstration asset.

The company's answer, for now, is to advance both tracks in parallel, using the therapeutic program's progress to de-risk the platform's value proposition for partners.

The Patient Population in View

For all the focus on imaging algorithms and seed rounds, the ultimate test for Stately Bio's technology will be in the clinic. The patient population that stands to benefit most directly from its internal pipeline are those with liver diseases awaiting regenerative solutions, a group that includes patients with end-stage liver failure for whom transplantation is the only current option. More broadly, the platform's potential impact extends to any condition being targeted by cell therapies, from certain cancers treated with CAR-T cells to degenerative diseases.

The standard of care in these areas today often involves invasive procedures, lifelong immunosuppression, or simply a lack of effective treatment. The development of those therapies, however, remains a painstaking, iterative process largely blind to the real-time biology of the therapeutic cells themselves. If Stately Bio's label-free window can make that process more predictable and efficient, it could meaningfully accelerate the timeline for getting new regenerative medicines to the patients who need them. The next twelve months will be about converting its seed capital into concrete platform partnerships and generating the external data required to move from a compelling prototype to an essential tool in the biotech toolkit.

Sources

  1. [Longevity.Technology, May 2025] Stately Bio launches to enhance cell therapy with ML-powered imaging | https://longevity.technology/news/stately-bio-launches-to-enhance-cell-therapy-with-ml-powered-imaging/
  2. [Bloomberg Markets, retrieved 2026] Frank Li, SoftBank Ventures Asia Corp: Profile and Biography | https://www.bloomberg.com/profile/person/22077692
  3. [TechCrunch, May 2015] Clinkle Implodes As Employees Quit In Protest Of CEO | https://techcrunch.com/2015/05/15/clunk/?_guc_consent_skip=1587425478

Read on Startuply.vc